-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA

Reuters·12/17/2025 21:05:50

Please log in to view news